BMO Capital Markets Raises Gilead Sciences (NASDAQ:GILD) Price Target to $115.00

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by BMO Capital Markets from $110.00 to $115.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 8.53% from the company’s previous close.

Several other analysts have also weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Robert W. Baird boosted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. UBS Group boosted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Stock Up 2.6 %

Shares of NASDAQ:GILD opened at $105.96 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a fifty day simple moving average of $93.38 and a 200 day simple moving average of $87.24. The firm has a market cap of $132.05 billion, a PE ratio of 1,177.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $106.43.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, equities research analysts anticipate that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 710,500 shares of company stock valued at $67,684,956. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.